Weekly Roundup - PHARMA - 6 January 2025 🔊BMS's Opdivo Qvantig FDA-Approved for Subcutaneous Use in NSCLC and Solid Tumors Bristol Myers Squibb's Opdivo Qvantig receives FDA approval for subcutaneous use in NSCLC and other solid tumors. The ...

Weekly Roundup - PHARMA - 6 January 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#FDA #Hikma #GLP1 #Victoza #EliLilly #Zepbound #ObesityTreatment #RhythmPharma #Setmelanotide #Imcivree #GeneticObesity #Pfizer #Braftovi #Humanteconomy #Humantec #KStrategyand